focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPearson Regulatory News (PSON)

Share Price Information for Pearson (PSON)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 958.20
Bid: 958.20
Ask: 958.60
Change: 0.20 (0.02%)
Spread: 0.40 (0.042%)
Open: 958.20
High: 964.40
Low: 955.40
Prev. Close: 958.00
PSON Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transaction in Own Shares

20 Sep 2023 13:24

RNS Number : 1024N
Pearson PLC
20 September 2023
 

20 September 2023

Pearson plc

 

Announcement of share repurchase programme

 

Further to its announcement on 31 July 2023 at its Interim Results, Pearson plc (the Company) announces the commencement of its £300 million share buyback programme (the Programme).

 

The Programme will commence tomorrow, 21 September 2023, and is anticipated to end on or before 7 March 2024 (the Engagement Period). Purchases may continue during any closed periods of the Company during the Engagement Period.

 

The Company has entered into an engagement with Citigroup Global Markets Limited (the Bank) under which it has issued a non-discretionary irrevocable instruction to the Bank to manage the share buyback programme. The Bank will carry out the instruction through the acquisition of ordinary shares in the Company for subsequent repurchase by the Company. The Bank will make trading decisions in relation to the Company's ordinary shares repurchased under the buyback programme independently of, and uninfluenced by, the Company.

 

Any acquisitions of its ordinary shares by the Company will be effected within certain pre-set parameters set out in the Bank's engagement letter, and in accordance with the Company's AGM authority to repurchase ordinary shares (at the AGM on 28 April 2023, shareholders gave the Company authority to purchase a maximum of 71,612,324 ordinary shares), Chapter 12 of the Financial Conduct Authority's Listing Rules and the provisions of the Market Abuse Regulation 596/2014/EU (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018, as amended).

 

The sole purpose of the Programme is to reduce the capital of the Company. As such, the Company will cancel any ordinary shares purchased.

 

For the avoidance of doubt, no repurchases will be made in respect of the Company's American Depositary Receipts.

 

The Bank may undertake transactions in the Company's ordinary shares during the Engagement Period in order to manage its market exposure under the Programme.

 

There is no change to the Group financial guidance for 2023 published by the Company in its Interim Results on 31 July 2023 and our medium-term Group level guidance is also unchanged.

 

Contacts

 

Investor Relations

Jo Russell

+44 (0) 7785 451 266

 

James Caddy

+44 (0) 7825 948 218

 

Gemma Terry

+44 (0) 7841 363 216

 

Brennan Matthews

+1 (332) 238-8785

Teneo

Charles Armitstead

+44 (0) 7703 330 269

 

Notes

Forward looking statements: Except for the historical information contained herein, the matters discussed in this statement include forward-looking statements. In particular, all statements that express forecasts, expectations and projections with respect to future matters, including trends in results of operations, margins, growth rates, overall market trends, the impact of interest or exchange rates, the availability of financing, anticipated cost savings and synergies and the execution of Pearson's strategy, are forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that will occur in future. They are based on numerous assumptions regarding Pearson's present and future business strategies and the environment in which it will operate in the future. There are a number of factors which could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including a number of factors outside Pearson's control. These include international, national and local conditions, as well as competition. They also include other risks detailed from time to time in Pearson's publicly-filed documents and you are advised to read, in particular, the risk factors set out in Pearson's latest annual report and accounts, which can be found on its website (www.pearsonplc.com). Any forward-looking statements speak only as of the date they are made, and Pearson gives no undertaking to update forward-looking statements to reflect any changes in its expectations with regard thereto or any changes to events, conditions or circumstances on which any such statement is based. Readers are cautioned not to place undue reliance on such forward-looking statements.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSBDGDCBDDDGXG
Date   Source Headline
28th Jul 20239:31 amRNSCommittee Changes
27th Jul 20239:48 amRNSDirector Declaration
19th Jul 20234:13 pmRNSDirector/PDMR Shareholding
4th Jul 20239:10 amRNSDirector/PDMR Shareholding
3rd Jul 20233:38 pmRNSTotal Voting Rights
14th Jun 20235:17 pmRNSHolding(s) in Company
1st Jun 202312:32 pmRNSBlock listing Interim Review
1st Jun 202312:28 pmRNSTotal Voting Rights
26th May 20234:48 pmRNSHolding(s) in Company
19th May 20233:00 pmRNSDirector/PDMR Shareholding
17th May 20234:50 pmRNSDirector/PDMR Shareholding
16th May 20234:16 pmRNSDirector/PDMR Shareholding
10th May 20234:30 pmRNSDirector/PDMR Shareholding
10th May 202310:49 amRNSDirectorate Change
9th May 20234:15 pmRNSHolding(s) in Company
9th May 20239:00 amRNSPearson: Generative AI Strategy Update
4th May 20234:30 pmRNSDirector/PDMR Shareholding
4th May 20234:30 pmRNSDirector/PDMR Shareholding
4th May 20234:30 pmRNSDirector/PDMR Shareholding
3rd May 20234:13 pmRNSHolding(s) in Company
2nd May 20233:57 pmRNSTotal Voting Rights
28th Apr 20231:11 pmRNSResult of AGM
28th Apr 20237:00 amRNSPearson 2023 Q1 Trading Update
20th Apr 20234:19 pmRNSHolding(s) in Company
11th Apr 20239:17 amRNSHolding(s) in Company
4th Apr 20234:30 pmRNSDirector/PDMR Shareholding
4th Apr 20234:00 pmRNSHolding(s) in Company
4th Apr 20237:00 amRNSDirector/PDMR Shareholding
3rd Apr 20233:00 pmRNSTotal Voting Rights
31st Mar 20233:44 pmRNSForm 20-F for the year ended 31 December 2022
31st Mar 20232:29 pmRNSHolding(s) in Company
28th Mar 202311:17 amRNSDirector Declaration
27th Mar 20234:05 pmRNSHolding(s) in Company
24th Mar 202312:30 pmRNSNotice of AGM
23rd Mar 20237:00 amRNSPearson Completes Acquisition of PDRI
21st Mar 20237:00 amRNSPearson to sell POLS
16th Mar 20233:09 pmRNSAnnual Financial Report
16th Mar 202311:28 amRNSDirector Declaration
7th Mar 20234:36 pmRNSDirector/PDMR Shareholding
3rd Mar 20237:00 amRNSPearson 2022 Preliminary Results
2nd Mar 20233:37 pmRNSCommittee Change
1st Mar 202310:10 amRNSTotal Voting Rights
8th Feb 20232:37 pmRNSHolding(s) in Company
3rd Feb 20234:23 pmRNSDirector/PDMR Shareholding
1st Feb 202311:10 amRNSTotal Voting Rights
18th Jan 20237:00 amRNSPearson 2022 Trading Update
4th Jan 20233:04 pmRNSDirector/PDMR Shareholding
3rd Jan 20239:25 amRNSTotal Voting Rights
19th Dec 202212:02 pmRNSDirector/PDMR Shareholding
19th Dec 202212:00 pmRNSPearson to Acquire PDRI

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.